Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

Inclusion Criteria

• Able and willing to complete the informed consent process
• Passes Test of Understanding
• 18 to 50 years of age
• Experiencing early acute HIV-1 infection as defined by blood samples on at least two separate days positive by nucleic acid testing within 21 days of a negative nucleic acid HIV-1 test OR by a positive nucleic acid test or a positive 4th generation enzyme immunoassay (EIA) in the context of a negative 2nd or negative 3rd generation HIV EIA test
• No history of antiretroviral therapy for any indication in the last 30 days.
• In general good health
• Willing to have blood samples collected and stored
• Able to participate for 25 weeks for study visits
• Willing to have photo or fingerprint taken for identification purposes

Female-Specific Criteria:

• Agrees not to become pregnant from the time of study enrollment until the last study visit. If a woman has no history of hysterectomy, tubal ligation or menopause, she must agree to use an effective birth control method: abstinence; male or female condoms; diaphragm or cervical cap with spermicide; intrauterine device; contraceptive hormones delivered by pills, patch, injections, or vaginally; and hormonal implants under the skin; or a male partner who has previously undergone a vasectomy.
• Negative beta-human chorionic gonadotropin (HCG) pregnancy test (urine or serum) on day of enrollment for any woman unless she is post-menopause for 24 consecutive months or has undergone a surgical procedure that precludes pregnancy

Exclusion Criteria

• Weight less than 46 kg or greater than 115 kg
• Previous receipt of humanized or human monoclonal antibody whether licensed or investigational
• Ongoing AIDS-related opportunistic infection (including oral thrush or active tuberculosis)
• Severe acute retroviral syndrome (as defined in Appendix I of the protocol) or clinical condition (other than HIV infection) constituting an indication for immediate antiretroviral therapy per local country guidelines
• Active injection drug use within previous 12 months
• History of a severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis in the 2 years prior to enrollment
• History of chronic urticaria
• Physical finding on examination considered indicative of significant disease such as murmur (other than functional), hepatosplenomegaly, focal neurological deficit
• Hypertension that is not well controlled by medication
• Positive hepatitis B surface antigen at any time in the past
• History of hepatitis C infection
• Untreated syphilis infection
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the upper limit of normal (ULN).
• Absolute neutrophil count (ANC) less than 740 cells/mm^3
• Estimated glomerular filtration rate (GFR) less than 50 ml/min within the past 90 days
• Breastfeeding
• Pregnancy
• Receipt of licensed vaccine or other investigational study agent within 28 days prior to enrollment or past participation in an investigational HIV vaccine study with receipt of active product
• Current or planned participation in another interventional clinical trial during the study period
• Chronic or recurrent use of medications that modify host immune response, e.g., oral or parenteral steroids, cancer chemotherapy
• Any other chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer. Including, but not limited to: diabetes mellitus type I, chronic hepatitis, renal failure; OR clinically significant forms of: drug or alcohol abuse, mental illness, severe asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer.
• Study site employee